Pfizer’s ABRYSVO RSV vaccine approved by FDA for broader adult use
The vaccine is now approved for adults aged 18 to 59 at higher risk of RSV-related respiratory illness, expanding its prior…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Pfizer
mRNA licensing agreements rise 800% in value as confidence grows beyond vaccines
With growing confidence in this technology, key companies are investing heavily in its potential to address unmet medical needs,…
S1P receptor modulators face uncertain future in Crohn’s disease amid trial setbacks
GlobalData’s Ulcerative Colitis Market Forecast expects Zeposia to have sales of $374.2 million worldwide in 2031, compared to…
Pfizer withdraws sickle cell disease treatment on risk of complication, death
Pfizer ends all studies and access to Oxbryta as risks outweigh benefits, based on clinical data
Pfizer sets up Analytics Gateway capability centre in India
The capability centre aims to accelerate Pfizer’s growth across the 140 countries (ex-US) where it is present, powered by data,…
FDA approves and authorises updated mRNA COVID-19 vaccines
The mRNA COVID-19 vaccines have been updated with a monovalent component that corresponds to the Omicron variant KP.2 strain…
Pfizer, BioNTech give update on mRNA-based combination vaccine programme
The combination candidate consists of Pfizer’s mRNA-based influenza vaccine candidate with the companies’ licensed COVID-19…
Pfizer’s RSV vaccine shows benefit in immuno-compromised adults in study
In a late-stage study, Pfizer’s Abrysvo vaccine generated robust antibodies against RSV-A and RSV-B in immunocompromised adults,…
Pfizer’s gene therapy for Haemophilia A receives positive topline results from Phase 3 Study
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Pfizer advances development of once-daily danuglipron
The company plans to conduct dose optimization studies with a focus on the preferred formulation to inform the registration…